Loading... Please wait...
About Us
Contact Us
Privacy Policy
Sign in
or
Create an account
My Account
View Cart
Checkout
Search
Home
Report Subject
Market Access
Browse by
Biosimilar Index
Dossier
FirstView
FirstView NPS+
FirstWord Pharma
Therapy Trends
Therapy Trends Updates
Latest Reports
Therapy Area Reports
Report Subject
Emerging Markets
Generics/Biosimilars
Market Access
Medical Affairs
Pharma Marketing
Pharma Sales
Technology/Digital Health
Orphan Drugs
Sort by:
Featured Items
Newest Items
Bestselling
Alphabetical: A to Z
Alphabetical: Z to A
FirstWord Market Access Reports
Next »
Pages:
1
2
3
4
5
6
Learn More
The Future of Key Account Management in Pharma
Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...
Compare
Learn More
Benchmarking Key Account Management Capabilities (2019)
What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...
Compare
Learn More
Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...
Compare
Learn More
Charting MSL Activity and Performance 2019
Understand which MSL activities are seen as being most important in the US and Western Europe Benchmark your own MSL programmes and identify new ways to improve performance Identify the most widely-used performance...
Compare
Learn More
Payer Engagement: Benchmarking Team Structure and Activity 2019
Is your payer engagement team appropriately experienced and resourced? What are the drivers that influence payer engagement team size and structure? What are the emerging challenges payer engagement teams will face...
Compare
Learn More
The Orphan Drug Fact File 2019
The Orphan Drugs Pipeline: Everything you need to know about current contenders and new opportunities By 2024, orphan drugs are expected to account for one fifth of worldwide prescription drug sales—some $242...
Compare
Learn More
Trends in KOL Experience Management
How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...
Compare
Learn More
Indication-level Pricing: Payer Insights
Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...
Compare
Learn More
KAM Metrics: Measuring Success (2019)
Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...
Compare
Learn More
MSL Teams: Field Force size and structure (2019)
What factors determine the optimum MSL field-based team size and structure? How many brands should MSL field-based teams represent and what constitutes an acceptable territory? What educational background and...
Compare
Learn More
Real World Data and Evidence: Payer Insights
Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...
Compare
Learn More
Review of Influence: The Institute for Clinical and Economic Review (ICER)
As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...
Compare
Learn More
Trends in Pharma-Patient Engagement
Exactly how is Pharma organising and benefitting from its patient engagement strategy? How are patient engagement teams structured and resourced? When do teams engage with patients and what are the main...
Compare
Learn More
Trends in Digital Pharma Marketing
What are the trends and developments that will drive pharma's digital marketing initiatives? What are the trends that are shaping digital pharma marketing? How will increased investment be used to drive the digital...
Compare
Learn More
Innovative drugs: Mapping the Pricing and Reimbursement Landscape
Health Technology Assessment (HTA) reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the US–but only...
Compare
Learn More
Market Access Team Structure and Function – Industry Survey (2019)
How are market access teams developing to meet evolving stakeholder demands? What are the trends that are defining market access skills? Which core competencies should teams be developing for the future? What market...
Compare
Learn More
Charting Real World Data and Evidence - Activity and Capabilities (2018)
How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing? Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2...
Compare
Learn More
The MSL Technology Survey (2018)
How is technology changing the face of MSL/KOL interaction and which technologies are set to take a greater role is this critical relationship? Which technologies are being employed to identify KOLs? What technology...
Compare
Learn More
HTA in Europe: Key Success Factors for Positive HTA Recommendations
Is there a magic formula for achieving HTA approvals in Europe? Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on...
Compare
Learn More
Paying for Digital Health: Payer Insights
Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...
Compare
Next »
Pages:
1
2
3
4
5
6
About Us
Contact Us
Privacy Policy
customer.service@firstwordpharma.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved